Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. A Novel Platform For Mutation Detection In Colorectal Cancer Using A Pna-lna Molecular Switch

A novel platform for mutation detection in colorectal cancer using a PNA-LNA molecular switch

Md Sajedul Islam1, Sharmin Aktar1, Neda Moetamedirad1

  • 1School of Medicine & Dentistry, Griffith University, Gold Coast Campus, Southport, QLD 4222, Australia.

Biosensors & Bioelectronics
|October 2, 2024

Related Experiment Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

634
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.0K

View abstract on PubMed

Summary
This summary is machine-generated.

A new PNA-LNA molecular switch platform rapidly detects KRAS mutations in colorectal cancer (CRC) with high sensitivity. This method offers a faster, cheaper, and more accessible tool for predicting targeted therapy response in CRC patients.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biotechnology

Background:

  • KRAS mutations in colorectal cancer (CRC) are crucial for predicting response to targeted therapies.
  • Accurate and sensitive detection of these mutations is essential for effective patient management.

Purpose of the Study:

  • To develop and validate a novel "PNA-LNA molecular switch" platform for detecting KRAS mutations in CRC.
  • To assess the platform's performance in terms of sensitivity, specificity, and reproducibility.

Main Methods:

  • Utilized peptide nucleic acid (PNA) and locked nucleic acid (LNA) with loop-mediated isothermal amplification (LAMP).
  • Designed to specifically amplify mutated KRAS oncogene codon 12 sequences while inhibiting wild-type amplification.
  • Assayed using synthetic oligonucleotides, cancer cell lines, and clinical samples (tumor tissue and circulating tumor cells).
Keywords:
Colorectal cancerIsothermal amplificationKRASLNA

Related Experiment Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

634
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.0K

Main Results:

  • The PNA-LNA platform demonstrated high specificity, amplifying mutated KRAS sequences effectively.
  • Achieved excellent sensitivity (1 DNA copy/μl), reproducibility (<5% RSD), and a wide linear dynamic range.
  • Colorimetric and fluorescence assays visualized mutation detection, validated against DNA sequencing.

Conclusions:

  • The PNA-LNA molecular switch is a sensitive, specific, and rapid method for KRAS mutation detection in CRC.
  • The platform is cost-effective, requires minimal equipment, and shows potential for clinical translation.
  • This technology could be applied to diverse disease mutation detection beyond CRC.
PNA